|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for IRF3 |
 Gene summary |
| Basic gene Info. | Gene symbol | IRF3 |
| Gene name | interferon regulatory factor 3 | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 19q13.3-q13.4 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001197122.1, NM_001197123.1,NM_001197124.1,NM_001197125.1,NM_001197126.1, NM_001197127.1,NM_001197128.1,NM_001571.5,NR_045568.1, | |
| Description | - | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 603734 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000126456 | ||
| HPRD : 04769 | ||
| Vega : OTTHUMG00000183287 | ||
| Protein | UniProt: Q14653 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_IRF3 | |
| BioGPS: 3661 | ||
| Pathway | NCI Pathway Interaction Database: IRF3 | |
| KEGG: IRF3 | ||
| REACTOME: IRF3 | ||
| Pathway Commons: IRF3 | ||
| Context | iHOP: IRF3 | |
| ligand binding site mutation search in PubMed: IRF3 | ||
| UCL Cancer Institute: IRF3 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for IRF3 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R81 | R81H | COAD | 1 | E94 | D95N | OV | 1 | H104 | P103S | OV | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for IRF3 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | H104 | P103S | -1.7719065 | R81 | R81H | -1.1509856 | E94 | D95N | -0.75285265 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for IRF3 from PDB |
| Top |
| Differential gene expression and gene-gene network for IRF3 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for IRF3 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for IRF3 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of IRF3 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 3qu6 | A | E94 H104 | ZN | ZINC(2+) | 3qu6 | B | E94 H104 | ZN | ZINC(2+) | 3qu6 | C | E94 H104 | NUC | Nucleic Acids | 1t2k | A | R81 | NUC | Nucleic Acids | 1t2k | B | R81 | NUC | Nucleic Acids | 2o6g | E | R81 | NUC | Nucleic Acids | 2o6g | F | R81 | NUC | Nucleic Acids | 2o6g | G | R81 | NUC | Nucleic Acids | 2o6g | H | R81 | NUC | Nucleic Acids | 2pi0 | A | R81 | NUC | Nucleic Acids | 2pi0 | B | R81 | NUC | Nucleic Acids | 2pi0 | C | R81 | NUC | Nucleic Acids | 2pi0 | D | R81 |
| Top |
| Conservation information for LBS of IRF3 |
| Multiple alignments for Q14653 in multiple species |
| LBS | AA sequence | # species | Species | A83 | RNFRSALNRKE | 3 | Homo sapiens, Mus musculus, Bos taurus | D17 | LVSQLDLGQLE | 2 | Homo sapiens, Mus musculus | D17 | LISQLDRGELE | 1 | Bos taurus | D99 | EDRSKDPHDPH | 1 | Homo sapiens | D99 | ADNSKDPYDPH | 1 | Mus musculus | D99 | EDHSKDSQDPH | 1 | Bos taurus | E94 | GLRLAEDRSKD | 1 | Homo sapiens | E94 | VLRLAADNSKD | 1 | Mus musculus | E94 | VLRLAEDHSKD | 1 | Bos taurus | F51 | AQQEDFGIFQA | 2 | Homo sapiens, Bos taurus | F51 | AQMADFGIFQA | 1 | Mus musculus | G41 | IPWKHGLRQDA | 3 | Homo sapiens, Mus musculus, Bos taurus | H101 | RSKDPHDPHKI | 1 | Homo sapiens | H101 | NSKDPYDPHKV | 1 | Mus musculus | H101 | HSKDSQDPHKI | 1 | Bos taurus | H104 | DPHDPHKIYEF | 1 | Homo sapiens | H104 | DPYDPHKVYEF | 1 | Mus musculus | H104 | DSQDPHKIYEF | 1 | Bos taurus | H40 | RIPWKHGLRQD | 3 | Homo sapiens, Mus musculus, Bos taurus | I8 | TPKPRILPWLV | 2 | Homo sapiens, Mus musculus | I8 | TQKPRILPWLI | 1 | Bos taurus | K105 | PHDPHKIYEFV | 1 | Homo sapiens | K105 | PYDPHKVYEFV | 1 | Mus musculus | K105 | SQDPHKIYEFV | 1 | Bos taurus | K5 | 3 | Homo sapiens, Mus musculus, Bos taurus | K77 | DLPTWKRNFRS | 2 | Homo sapiens, Bos taurus | K77 | DVSTWKRNFRS | 1 | Mus musculus | K87 | SALNRKEVLRL | 2 | Mus musculus, Bos taurus | K87 | SALNRKEGLRL | 1 | Homo sapiens | K98 | AEDRSKDPHDP | 1 | Homo sapiens | K98 | AADNSKDPYDP | 1 | Mus musculus | K98 | AEDHSKDSQDP | 1 | Bos taurus | L42 | PWKHGLRQDAQ | 3 | Homo sapiens, Mus musculus, Bos taurus | N79 | PTWKRNFRSAL | 2 | Homo sapiens, Bos taurus | N79 | STWKRNFRSAL | 1 | Mus musculus | N85 | FRSALNRKEVL | 2 | Mus musculus, Bos taurus | N85 | FRSALNRKEGL | 1 | Homo sapiens | P4 | 3 | Homo sapiens, Mus musculus, Bos taurus | P6 | MGTPKPRILPW | 1 | Homo sapiens | P6 | METPKPRILPW | 1 | Mus musculus | P6 | MGTQKPRILPW | 1 | Bos taurus | P74 | DKPDLPTWKRN | 2 | Homo sapiens, Bos taurus | P74 | DKPDVSTWKRN | 1 | Mus musculus | Q44 | KHGLRQDAQQE | 2 | Homo sapiens, Bos taurus | Q44 | KHGLRQDAQMA | 1 | Mus musculus | R43 | WKHGLRQDAQQ | 2 | Homo sapiens, Bos taurus | R43 | WKHGLRQDAQM | 1 | Mus musculus | R7 | GTPKPRILPWL | 1 | Homo sapiens | R7 | ETPKPRILPWL | 1 | Mus musculus | R7 | GTQKPRILPWL | 1 | Bos taurus | R78 | LPTWKRNFRSA | 2 | Homo sapiens, Bos taurus | R78 | VSTWKRNFRSA | 1 | Mus musculus | R81 | WKRNFRSALNR | 3 | Homo sapiens, Mus musculus, Bos taurus | R86 | RSALNRKEVLR | 2 | Mus musculus, Bos taurus | R86 | RSALNRKEGLR | 1 | Homo sapiens | S82 | KRNFRSALNRK | 3 | Homo sapiens, Mus musculus, Bos taurus | T61 | AWAEATGAYVP | 1 | Homo sapiens | T61 | AWAEASGAYTP | 1 | Mus musculus | T61 | AWAVASGAYTP | 1 | Bos taurus | V13 | ILPWLVSQLDL | 2 | Homo sapiens, Mus musculus | V13 | ILPWLISQLDR | 1 | Bos taurus | W38 | RFRIPWKHGLR | 3 | Homo sapiens, Mus musculus, Bos taurus | W57 | GIFQAWAEATG | 1 | Homo sapiens | W57 | GIFQAWAEASG | 1 | Mus musculus | W57 | GIFQAWAVASG | 1 | Bos taurus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |